BACKGROUND It is common practice to use prostate specific antigen (PSA) ≥4.0 ng/ml as a clinical indicator for men at risk of prostate cancer (PCa), however, this is unverified in HIV+ men. We aimed to describe kinetics and predictive value of PSA for PCa in HIV+ men. METHODS A nested case control study of 21 men with PCa and 40 matched-controls within EuroSIDA was conducted. Prospectively st...

Although the value of prostate-specific antigen (PSA) velocity or doubling time has never been seriously questioned for aiding the clinical management of recurrent or advanced cancer, there has historically been considerable uncertainty about PSA kinetics for decisions about biopsy and initial treatment. Recent studies, including analyses of cohorts from all the major randomized trials of local...

Salvage radiotherapy (SRT) has been successfully used for recurrent prostate cancer after radical prostatectomy; however, the optimal timing of SRT remains controversial. Our objective was to identify the risk factors for disease progression after SRT, with a focus on the pre-SRT prostate-specific antigen (PSA) levels in the modern era of PSA testing. We performed a retrospective review of 551 ...

BACKGROUND Patients with early stage prostate cancer have a variety of curative radiotherapy options, including conventionally-fractionated external beam radiotherapy (CF-EBRT) and hypofractionated stereotactic body radiotherapy (SBRT). Although results of CF-EBRT are well known, the use of SBRT for prostate cancer is a more recent development, and long-term follow-up is not yet available. Howe...

BACKGROUND The purpose of this study was to validate the use of whole-blood samples in the determination of circulating forms of prostate-specific antigen (PSA). METHODS Blood samples of hospitalized prostate cancer and benign prostatic hyperplasia patients were collected and processed to generate whole-blood and serum samples. Three different rapid two-site immunoassays were developed to mea...

Clinically diagnosed Prostate cancer is suspected due to raised PSA and abnormal DRE. DRE detected prostate cancer is often advanced and not amenable to curative treatment. The use of PSA as a serum marker has revolutionized PCa diagnosis. PSA is specific to the gland but not specific to cancer, therefore, it may be elevated in benign prostatic hypertrophy (BPH), prostatitis and other nonmalign...

Pseudopterosin A (PsA) treatment of growth factor depleted human umbilical vein endothelial cell (HUVEC) cultures formulated in hydroxypropyl-β-cyclodextrin (HPβCD) for 42 h unexpectedly produced a 25% increase in cell proliferation (EC₅₀ = 1.34 × 10⁻⁸ M). Analysis of dose response curves revealed pseudo-first order saturation kinetics, and the uncoupling of cytotoxicity from cell proliferation...

The determination of kinetic binding constants for antibody-antigen interactions is critical in many research and development applications. OpenSPR allows users to easily and accurately measure the binding kinetics of numerous ligand-antigen systems. In this application note, OpenSPR is used to determine the on and off rates and affinity constant for the interaction between prostate specific an...

The determination of kinetic binding constants for antibody-antigen interactions is critical in many research and development applications. OpenSPR allows users to easily and accurately measure the binding kinetics of numerous ligand-antigen systems. In this application note, OpenSPR is used to determine the on and off rates and affinity constant for the interaction between prostate specific an...